Immunotherapy with cat- and dog-dander extracts

Hedlin, Gunilla; Graff‐Lonnevig, V.; Heilborn, H.; Lilja, G.; Norrlind, K.; Pegelow, Kjell-Orvar; Sundin, Bo; Løwenstein, Henning

doi:10.1016/0091-6749(91)90417-m

Cited by 133 publications

(59 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since immunotherapy often reduces the reactivity of the skin and the release of histamine from peripheral basophils, the release of mediators from mast cells in the airway might be also suppressed [50,51]. This hypothesis was supported by the observations that the concentration of mast cell-derived tryptase in the nasal lavage fluid after allergen provocation was decreased by successful immunotherapy [52].…”

Section: Discussionsupporting

confidence: 63%

Effects of oral hyposensitization with recombinant Der f2 on immediate airway constriction in a murine allergic model

Yasue

Yokota²,

Yuasa³

et al. 1998

Eur Respir J

View full text Add to dashboard Cite

Recombinant Der f2 (rDer f2) has recently been developed as a promising allergen for the diagnosis and immunotherapy of house-dust mite allergy, and studies in immunology. The aim of the present study was to evaluate whether oral administration of rDer f2 could suppress an immediate allergic reaction in mice sensitized with mite allergen. We developed a murine allergic model that showed bronchoconstriction after inhalation of rDer f2, and studied the effect of oral administration of rDer f2 on the reaction.Seven week old male A/J mice were intranasally immunized with rDer f2 12 times. Sensitized mice showed anti-rDer f2 immunoglobulin (Ig)E production and immediate airway constriction after inhalation of 10 mg·mL -1 of rDer f2, as determined by the Konzett-Rössler method. Immunized animals were divided into three groups, and fed phosphate-buffered saline (PBS), 0.1 mg·day -1 , or 1 mg·day -1 of rDer f2 for 4 weeks, respectively. Seven days after the last feeding, the mice were examined for their immediate response.Animals fed with 1 mg·day -1 rDer f2 showed significantly reduced bronchoconstriction after inhalation of both 2 mg·mL -1 and 10 mg·mL -1 of rDer f2 compared with PBS-fed mice. Similar results were obtained when we examined mice 10 weeks after the last feeding. Reactions in the 0.1 mg·day -1 rDer f2-fed group also tended to decrease in comparison with PBS-fed animals. Plasma anti-rDer f2 IgE, IgG1, IgG2a, and IgG2b levels were not changed by feeding with rDer f2.We conclude that recombinant Der f2 exhibits both sensitizing and hyposensitizing activities in mice. rDer f2 may be useful in immunotherapy and diagnosis of housedust mite allergy. Eur Respir J 1998; 11: 144-150 To date, several clinically important allergens such as Der 1 and Der 2 have been identified in crude mite extract [1][2][3][4]. Among others, the structural gene of Der f2, one of the major mite allergens found in Dermatophagoides farinae was cloned, and the product (recombinant Der f2 (rDer f2)) shown to exhibit allergic activity in humans comparable with native Der f2 prepared from crude mite extract [5,6]. Since Der f2 has been shown to sensitize over 80% of patients with house-dust mite allergy, rDer f2 should prove useful in the diagnosis and immunotherapy of allergic asthma and rhinitis caused by house-dust mites. It should also provide a basis for research into allergies and immunology.In the present study, with special reference to the therapeutic application of rDer f2, we established a murine allergic model by intranasal or intraperitoneal injection of rDer f2 to A/J mice, which are highly responsive to Der f2 [7]. We examined the effect of oral-hyposensitization therapy with rDer f2 against the immediate bronchoconstriction in the intranasally sensitized animals because their reaction after rDer f2 inhalation was more intense than that of intraperitoneally immunized mice. Materials and methodsAntigen rDer f2, clone 1 [5], was kindly supplied by the Nikka Whisky Distilling Co., Ltd. (Chiba, Japan), and dissolved in...

show abstract

Section: Discussionsupporting

confidence: 63%

Effects of oral hyposensitization with recombinant Der f2 on immediate airway constriction in a murine allergic model

Yasue

Yokota²,

Yuasa³

et al. 1998

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Treatment of cat allergy by allergen injections is often employed, but clinical results are, in part, controversial. Because only crude dander extract is available for the treatment of cat allergy (4,5), alternative formulations have been proposed (6,7).…”

mentioning

confidence: 99%

Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in Escherichia coli

Grönlund

Bergman

Sandström

et al. 2003

Journal of Biological Chemistry

102

View full text Add to dashboard Cite

“…In the early 1980s, we performed a double-blind, placebo-controlled study of children and adults with cat or dog dander allergy, and mild to moderate asthma. The treatment consisted of standardized extracts and the patients carried out bronchial allergen and histamine challenges [Hedlin et al 1991]. The effect of SCIT was very good and mixed, with the cat extract having a beneficial effect both on allergen sensitivity and BHR, while the dog extract had only some effect on allergen sensitivity but no effect on BHR.…”

Section: Immunotherapy For Mild Asthma and Allergic Rhinitis To Impromentioning

confidence: 99%

The role of immunotherapy in the management of childhood asthma

Hedlin

Hage

2012

Ther Adv Respir Dis

View full text Add to dashboard Cite

Subcutaneous immunotherapy (SCIT) is still questioned as a safe and efficacious way of treating allergic asthma in children. In a Cochrane review published in 2010 it was, however, concluded that SCIT has significant and beneficial effects on symptoms and medication use in both children and adults with mostly mild asthma. Only a few studies have been performed to specifically study if SCIT in children with moderate asthma reduces the need for inhaled corticosteroids. There are conflicting results that illustrate the problem of the heterogeneity of the asthma disease and the fact that allergies may play different roles on the severity and symptoms of the disease. Furthermore, children with severe allergic asthma are often sensitized to multiple allergens, which makes SCIT both complicated and less safe to administer. On the other hand, if the child suffers from asthmatic symptoms despite adherence to pharmacotherapy, omalizumab or a combination of omalizumab and allergen immunotherapy might be useful. There is a need for more studies on this combination before it can be considered as an additional therapy in children with asthma and severe allergies. Sublingual immunotherapy (SLIT) has also been shown to improve asthma symptoms and medication use. SLIT is safe although its efficacy compared with SCIT has been studied very little. Another approach is to try to prevent asthma by treating children with SCIT for allergic rhinoconjunctivitis before asthma has developed. The most attractive prospect, however, is to find ways of preventing asthma by vaccination against the most common viruses, particularly rhinovirus. There is evidence that there are children at high risk of developing asthma in whom a viral infection can also enhance the risk of allergen sensitization. So far this vaccination has not been achievable although research is in progress.

show abstract

Immunotherapy with cat- and dog-dander extracts

Cited by 133 publications

References 17 publications

Effects of oral hyposensitization with recombinant Der f2 on immediate airway constriction in a murine allergic model

Effects of oral hyposensitization with recombinant Der f2 on immediate airway constriction in a murine allergic model

Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in Escherichia coli

The role of immunotherapy in the management of childhood asthma

Contact Info

Product

Resources

About